Friday, March 13, 2015

New Problem with Lyme in RI, again!


This is an important issue especially for Lyme patients in Rhode Island. However, legal precedents set in one state will not necessarily affect legislation around patients' rights in other states. Therefore, I have decided to repost this request on my blog. This originally came into me through a physicians' listserv that I participate in. The issue and the request by the author are self-explanatory, as you'll see below. 

-Bob

From:
Elaine Mullen Cassinelli RNBS.  Independent researcher.  

Hi All,

Rhode Island Lyme patients and all those who believe in a patient's freedom to obtain treatment need your help!!  Several weeks ago, we were elated  to learn that Dr. Michael Fine, the prior head of the Rhode Island Department of Health, who was director during the trumped-up investigation of Dr. James Gloor, a Lyme literate doctor, was stepping down.  However the new nominee for the position, chosen by Governor Gina Raimondo, is Dr.Nicole Alexander, the Infectious Disease Doctor who was responsible for sending out emails to dozens of physicians literally trolling for complaints against Dr. Gloor, in a way that was clearly contradictory to Rhode Island law!  Dr Alexander was working at Brown University, as well as acting as a consultant for the Department of Health, at the time she sent this email out, in clear violation of the rules of confidentiality of the board of medical licensure. She is not only not Lyme literate, she is hostile to the treatment of Lyme.

I am asking anyone who cares about these issues to PLEASE write a quick email to both Governor Raimondo and the Rhode Island senators who will be voting to approve or reject her nominee. If anyone would like to see the email that Dr. Alexander wrote, I would be happy to provide that. I am very much afraid that getting treatment for Lyme disease in Rhode Island is about to get harder unless we oppose this nomination. I will also let everyone know when the nomination hearing will be if anyone wants to attend or even to testify.  THANK YOU!!

Governor Gina Raimondo Office of the Governor 82 Smith Street Providence, RI 02903 email:brad.inman@governor.ri.gov.  Phone: (401) 222-2080 Fax: (401) 222-8096

New test for early detection of Lyme infection

This seems promising as a means of testing potentially-infected patients shortly after a suspected tick bite. 

-Bob

Clin Infect Dis. 2015 Mar 11. pii: civ185. [Epub ahead of print]
Development of a metabolic biosignature for detection of early Lyme disease.
Molins CR1, Ashton LV2, Wormser GP3, Hess AM4, Delorey MJ1, Mahapatra S2, Schriefer ME1, Belisle JT5.

 

Early Lyme disease patients often present to the clinic prior to developing a detectable antibody response to Borrelia burgdorferi, the etiologic agent. Thus, existing two-tier serology-based assays yield low sensitivities (29-40%) for early infection. The lack of an accurate laboratory test for early Lyme disease contributes to misconceptions about diagnosis and treatment, and underscores the need for new diagnostic approaches.
 
METHODS:
Retrospective serum samples from patients with early Lyme disease, other diseases, and healthy controls were analyzed for small molecule metabolites by liquid chromatography-mass spectrometry (LC-MS). A metabolomics data workflow was applied to select a biosignature for classifying early Lyme disease and non-Lyme disease patients. A statistical model of the biosignature was trained using the patients' LC-MS data, and subsequently applied as an experimental diagnostic tool with LC-MS data from additional patient sera. The accuracy of this method was compared with standard two-tier serology.
 
RESULTS:
Metabolic biosignature development selected 95 molecular features that distinguished early Lyme disease patients from healthy controls. Statistical modeling reduced the biosignature to 44 molecular features, and correctly classified early Lyme disease patients and healthy controls with a sensitivity of 88% (84-95%), and a specificity of 95% (90-100%). Importantly, the metabolic biosignature correctly classified 77-95% of the of serology negative Lyme disease patients.
 
CONCLUSION:
The data provide proof-of-concept that metabolic profiling for early Lyme disease can achieve significantly greater (p<0.0001) diagnostic sensitivity than current two-tier serology, while retaining high specificity.
 
PMID: 25761869

Tuesday, March 10, 2015

New Lyme bacteria test, very fast results....

This study looks promising. A new, real-time (no waiting for weeks for a Bb culture test) test for Lyme bacteria (Borrelia miyamotoi, which is only one of many Borrelia species, but good enough for a proof-of-concept) seems to have been developed in Austria. Read on....

-Bob


Ticks Tick Borne Dis. 2015 Feb 23. pii: S1877-959X(15)00028-X. doi:
10.1016/j.ttbdis.2015.02.002. [Epub ahead of print]

A newly established real-time PCR for detection of Borrelia miyamotoi in Ixodes ricinus ticks.

Reiter M1, Schötta AM2, Müller A2, Stockinger H2, Stanek G2.

Author information

   1Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Kinderspitalgasse 15, 1090 Vienna, Austria. Electronic address: michael.a.reiter@meduniwien.ac.at.
   2Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Kinderspitalgasse 15, 1090 Vienna, Austria.

Abstract

A total of 350 ticks collected in Austria were analyzed for the presence of DNA sequences of B. miyamotoi. Three ticks gave positive results in a B. miyamotoi-specific nested PCR. Results were confirmed by sequencing the amplified glpQ gene from the positive samples.
Moreover we developed a real-time PCR which unambiguously detected B. miyamotoi in all positive samples. Further genotyping of the samples found 100% identity of the 16S-23S intergenic spacer region with Swedish B. miyamotoi sequences.
This is the first detection of the relapsing fever spirochete Borrelia miyamotoi in hard ticks in Austria. The results consolidate the picture of a European-wide distribution of B. miyamotoi and again underscore the need for clinical awareness to clarify possible involvement of this species in human disease.

Copyright © 2015 Elsevier GmbH. All rights reserved.
KEYWORDS:

Borrelia; Ixodes; Miyamotoi; PCR; Tick

PMID:
   25736476
   [PubMed - as supplied by publisher]

Lyme CNS Infection Mimics Stroke in Teenager

Medscape Medical News

(C) Medscape Medical News, (c) Annals Emerg Med

Lyme CNS Infection Mimics Stroke in Teenager

Janis C. Kelly

March 06, 2015


http://www.medscape.com/viewarticle/841010


The chameleon qualities of Lyme neuroborreliosis gained another layer with a case report of a teenager with sudden onset of what appeared to be ischemic stroke but turned out to be Borrelia burgdorferi infection. The correct diagnosis was made just in time to avoid the administration of thrombolytic therapy to the teenager.


Arseny A. Sokolov, MD, from the Department of Clinical Neuroscience, Centre Hospitalier Universitaire Vaudois, Lausanne , Switzerland , and colleagues reported in an article published online February 25 in the Annals of Emergency Medicine that the 16-year-old girl presented the morning after a disco party with acute onset of severe headache and confusion. By the time she was evaluated at an urgent care center, she had right-sided face and arm weakness and language deficits. She was transferred by helicopter to a medical center for possible thrombolysis.


"Everything about her symptoms indicated stroke: speech deficits, poor comprehension and right-sided face and arm weakness, so we considered treating her with clot-busting drugs. But a 16 year-old having a stroke, while not unheard of, would be quite rare so we looked at other possibilities and found Lyme," Dr Sokolov said in a news release.


By 3 hours after symptom onset, the hemiparesis had resolved, but the patient still displayed agitation, confusion, and aggressiveness. She had reduced ability to speak but no meningismus. Motor and sensory deficits had resolved, and the patient had normal reflexes and other neurological examinations.


"The language deficits with reduced speech production and comprehension but preserved repetition were compatible with transcortical sensory aphasia," the authors write. "Although right-sided face and arm weakness could not be confirmed, both language and motor symptoms pointed to focal left parietotemporal affection, with ischemic stroke and nonconvulsive status epilepticus to be excluded first. Although thrombolytic treatment in pediatric stroke is an evolving area, the patient would have been within the European 4.5-hour window in which thrombolysis has been effective in adults."


Drug intoxication and psychogenic origin were ruled out because the patient had been directly observed for at least 16 hours before hospital admission.


In view of the possible indication for thrombolysis, Dr Sokolov's team conducted contrast-enhanced brain computed tomography with arterial and venous angiographies, which showed no signs of brain lesion, hemorrhagic stroke, vasculitis, or cerebral venous sinus thrombosis but did reveal diffuse brain hyperperfusion with patchy perfusion in the left temporoparietal junction. Given the imaging results, the clinicians concluded that thrombolysis was not indicated. They ruled out nonconvulsive status epilepticus by electroencephalography and drug or other toxicity by extensive toxicologic screening.


"The imaging findings for the first time demonstrate acute brain dysfunction that appears to be directly related to neuroborreliosis," coauthor Renaud Du Pasquier, MD, neurology chairman at the Centre Hospitalier Universitaire Vaudois in Lausanne , said in the news release. "It may point out future perspectives for research on the underlying mechanisms."


The next step in the diagnosis was lumbar puncture. Cerebrospinal fluid (CSF) analysis showed elevated leucocyte levels with 45% neutrophils, elevated protein, and elevated lactate, along with reduced CSF glucose. The researchers concluded that despite the relatively low leucocyte counts and unremarkable Gram stain, the patient might have bacterial meningitis.


The patient was quickly treated with an intravenous regimen of ceftriaxone, amoxicillin/clavulanate, and acyclovir and began to improve almost immediately.


Within 24 hours, symptoms had resolved, apart from circumstantial amnesia. Blood immunoassays for B burgdorferi immunoglobulin G, immunoglobulin M, and C6 Lyme immunoglobulin were positive. Intrathecal production of immunoglobulin G was observed using isoelectrofocalization, and highly significant levels of B burgdorferi  immunoglobulin M and immunoglobulin G were identified in CSF and serum, yielding an intrathecal antibody index of 7.1 (vs normal <1.5). The CXCL13 chemokine in CSF was nearly double normal levels.

Despite the absence of a history of tick bite, the researchers concluded the patient had acute neuroborreliosis. They continued ceftriaxone alone for 4 weeks, by which time the patient had achieved "excellent clinical evolution."


The authors emphasize that this report "highlights the importance of lumbar puncture and early empiric antimicrobial treatment" to avoid complications such as chronic Lyme encephalopathy with cognitive deficits. They also suggest that CXCL13 might be a particularly useful early marker of Lyme neuroborreliosis before positive tests for intrathecal antibodies because CXCL13 is secreted afterBorrelia invasion of the central nervous system and attracts B lymphocytes.


The authors have disclosed no relevant financial relationships.

Annals Emerg Med. Published online February 25, 2015. Full text


1 comment

Tim Rhudy| Other Healthcare Provider16 hours ago

Lyme is a great imitator and a great detonator. When the ridiculous bad testing is finally acknowledged and the medical culture shifts towards greater recognition (when the old guard dies off if Max Planck is correct), we will be seeing a lot more of these stories.

Apple Introduces ResearchKit, Giving Medical Researchers New Tools

Date: March 9, 2015 3:07:41 PM PDT
Subject: Apple Introduces ResearchKit, Giving Medical Researchers New Tools
Source: Apple Hot News

Apple today announced ResearchKit, an open-source software framework designed for medical and health research that can help doctors and scientists gather data more frequently and more accurately from participants using iPhone apps. World-class research institutions have already developed apps with ResearchKit for studies on asthma, breast cancer, cardiovascular disease, diabetes, and Parkinson's disease. "iOS apps already help millions of customers track and improve their health. With hundreds of millions of iPhones in use around the world, we saw an opportunity for Apple to have an even greater impact by empowering people to participate in and contribute to medical research," said Jeff Williams, Apple's senior vice president of Operations. "ResearchKit gives the scientific community access to a diverse, global population and more ways to collect data than ever before."

Read more…

Thursday, March 5, 2015

Harvard team success with stem cells for Parkinson's disease

Harvard Stem Cell Institute (HSCI) researchers at University-affiliated McLean Hospital have taken what they describe as an important step toward using the implantation of stem cell-generated neurons as a treatment for Parkinson's disease.

Ole Isacson and colleagues reported that dopamine-producing neurons derived from the skin cells of primates survived for more than two years after implantation into one of the animals, and markedly reduced its Parkinson's symptoms. The primate did not require immunosuppression, the scientists reported in the journal Cell Stem Cell.

Read the full story here:

Wednesday, March 4, 2015

Dr R. Stricker (LLMD) comment on recent Lyme article on Pub Med

A recent article (Jan 5, 2015) on Lyme bacteria persistence after antibiotic treatment went up Pub Med. Noted LLMD and researcher Dr Raphael Stricker responded to the article with a letter you can read below. If you want to see the study he is referring to, explore the two links below. This article (report) is viewable without having a PubMed account. Anyone may view it.  -Bob


 

Shapiro ED.F1000Prime Rep. 2015.1 comment

In this one-sided opinion piece about Lyme disease, Eugene Shapiro once again finds "no evidence that viable B. burgdorferi persist in humans after conventional treatment with antimicrobials". Shapiro is a well known member of the shrinking "Lyme Denialist" cabal that views Lyme disease as a trivial illness that is "hard to catch and easy to cure", apparently ignoring the latest CDC figures showing more than 300,000 new cases per year in the USA. The fact that Lyme disease has become a major epidemic that is six times more common than HIV/AIDS in this country fails to impress Shapiro, who adheres to the dogma that persistent infection with B. burgdorferi, the Lyme spirochete, does not exist following short-course antibiotic therapy despite extensive evidence to the contrary (Stricker & Johnson, Infect Drug Resist 4: 1-9, 2011; Cameron et al, Expert Rev. Anti Infect. Ther. 12:1103-1135, 2014).

Significant controversy over Lyme disease exists for three main reasons: (1) lack of accurate and/or universally accepted testing for the disease, (2) disagreement about symptoms associated with persistent infection in chronic Lyme disease, and (3) misinterpretation and misrepresentation of underpowered Lyme antibiotic treatment trials. While many studies describe the constellation of musculoskeletal, neurocognitive and/or cardiac symptoms associated with chronic Lyme disease, Shapiro views these as "medically unexplained symptoms" not necessarily related to persistent B. burgdorferi infection. Without a universally accepted "gold standard" test, the controversy over persistent infection and optimal therapy continues to smoulder while thousands of patients continue to suffer due to the dogma espoused by Shapiro (Johnson et al. PeerJ 2:e322, 2014).

A major problem faced by Shapiro is that he is trying to prove a negative. Thus if there is any evidence that persistent infection with B. burgdorferi does exist following short-course antibiotic therapy, his opinion is obviously wrong. To address this problem, Shapiro narrows his evidence to two recent Lyme disease articles, ignoring numerous studies in animals and humans that support persistent infection or leave the issue unsettled (Cairns & Godwin, Int J Epidemiol 34: 1340-1345, 2005; Berndtson, Int J Gen Med 6: 291-306, 2013; Stricker & Johnson, PLoS Pathog 10: e1003796, 2014). Shapiro dismisses this contrary evidence as "speculative", but his narrow selection of two "convincing" studies is insufficient to support his biased conclusion.

The first study examined a group of 17 patients with recurrent erythema migrans (EM) rashes who were promptly treated for their initial episode of Lyme disease and then developed one or more EM rashes at a later date. Culture of the rashes revealed different strains of B. burgdorferi in the subsequent episodes, and Shapiro points to this as evidence for new infection rather than relapse in these patients. However as pointed out in a letter addressing the article, this is a poor model for chronic Lyme disease due to persistent infection because all patients were promptly treated for their initial illness, lived in endemic areas and most likely were reinfected with a different strain of the spirochete from a subsequent tickbite. This is a very different situation from a patient who may have been infected and never treated for months to years and develops the constellation of musculoskeletal, neurocognitive and/or cardiac symptoms that are characteristic of persistent infection with the Lyme spirochete (Donta, N Engl J Med 368:1063-1064, 2013). Thus the model for persistent infection in this study is flawed.

The second study was a xenodiagnosis safety study of 36 patients (26 Lyme patients in different stages of disease and 10 controls) who allowed ticks to feed on them, and the ticks were then examined for B. burgdorferi transmission. Shapiro states that "no viable B. burgdorferi were cultured from ticks fed on any of these patients". This conclusion is flawed for two reasons: First, 30-50% of ticks were lost during the study, rendering the transmission results uninterpretable. Second, one patient with post-treatment Lyme disease syndrome (PTLDS) was found to have a positive culture from one tick, as stated in the Results: "One nymph was found to be positive by PCR of the nymph lysate culture, but direct PCR of the nymph lysate and microscopic evaluation of the culture were negative....The original positive OspA PCR of the tick culture was confirmed by PCRs for other B. burgdorferi genes.... The DNA extracted from this culture sample was then tested by IA/PCR/ESI-MS, which was positive for 7 of the 8 assay primer pairs" (emphasis added). Thus this patient had culture-confirmed evidence of persistent infection with the Lyme spirochete in PTLDS. Shapiro generously states that this finding is "provocative" when in fact it provides definitive evidence that he is wrong.

In summary, this one-sided opinion piece will only add to the confusion and misinformation surrounding Lyme disease. With better testing and novel treatments, a solution to this tickborne disease will someday be found. Shapiro's muddled article fails to contribute to this solution.

Antibiotics seem to effectively treat some cancers

This just came to my attention today. This does not directly concern Lyme disease treatment, but since there's such a concern about the overuse of antibiotics, I thought it was relevant.  -Bob

Researchers have been studying cancer as an infectious disease and have finally determined after another clinical trial that a number of cancers respond favorably to antibiotics that are already FDA approved and on the market.  

QUOTE from most recent study- "Based on this analysis, we now show that 4-to-5 different classes of FDA-approved drugs can be used to eradicate cancer stem cells, in 12 different cancer cell lines, across 8 different tumor types (breast, DCIS, ovarian, prostate, lung, pancreatic, melanoma, and glioblastoma (brain)).  These five classes of mitochondrially-targeted antibiotics include: the erythromycins, the tetracyclines, the glycylcyclines, an anti-parasitic drug, and chloramphenicol." 

Here are some of the original studies. You will find the early mouse studies here- very interesting- and the article with them is easy to read. 

https://sites.google.com/site/marylandlyme/lyme/cancer-doxycycline-studies

Here is the latest published study with more good news, including the quote posted above.  

https://sites.google.com/site/marylandlyme/lyme/cancer-doxycycline-studies/treating-cancer-like-an-infectious-disease